Clinical trials
Completed Bacteremia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
50 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 2 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 7 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 50 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Pittsburgh | 4 |
| Duke University | 3 |
| Accelerate Diagnostics, Inc. | 2 |
| ContraFect | 2 |
| Johns Hopkins University | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | 2 |
| T2 Biosystems | 2 |
| Anderson Clinical Research | 1 |
| Armata Pharmaceuticals, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bacteremia | 50 |
| Sepsis | 12 |
| Staphylococcal Infections | 10 |
| Infections | 5 |
| Fungemia | 3 |
| HIV Infections | 3 |
| Mycobacterium avium-intracellulare Infection | 3 |
| Urinary Tract Infections | 3 |
| AIDS-Related Opportunistic Infections | 2 |
| Acquired Immunodeficiency Syndrome | 2 |
Trials
Showing 1 to 25 of 50. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.